ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 127,16
0,87%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Reata Pharmaceuticals Inc (RETA)

  7. Reata Pharmaceuticals Inc (RETA) Actualités

RETA

Reata Pharmaceuticals (RETA)

Reata Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RETA
DateHeureSourceTitreSymboleSociété
06/10/202322h07Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:RETAReata Pharmaceuticals Inc
28/09/202322h30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RETAReata Pharmaceuticals Inc
27/09/202301h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202323h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202322h25Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202322h23Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202314h59GlobeNewswire Inc.Biogen Completes Acquisition of Reata PharmaceuticalsNASDAQ:RETAReata Pharmaceuticals Inc
21/09/202316h08Business WireReata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.NASDAQ:RETAReata Pharmaceuticals Inc
14/09/202322h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RETAReata Pharmaceuticals Inc
12/09/202319h20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RETAReata Pharmaceuticals Inc
22/08/202314h00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:RETAReata Pharmaceuticals Inc
11/08/202322h38Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:RETAReata Pharmaceuticals Inc
31/07/202313h20IH Market NewsMonday’s Wall Street Highlights: Palantir Technologies, Walmart, Yellow Corp, J&J, and moreNASDAQ:RETAReata Pharmaceuticals Inc
28/07/202313h05GlobeNewswire Inc.Biogen to Acquire Reata PharmaceuticalsNASDAQ:RETAReata Pharmaceuticals Inc
28/06/202313h20Dow Jones NewsReata Pharma Shares Climb Premarket After FDA OKs Prior-Approval Supplement for SkyclarysNASDAQ:RETAReata Pharmaceuticals Inc
28/06/202301h29Business WireReata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s AtaxiaNASDAQ:RETAReata Pharmaceuticals Inc
26/06/202322h47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RETAReata Pharmaceuticals Inc
16/06/202322h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RETAReata Pharmaceuticals Inc
16/06/202301h15Business WireReata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval SupplementNASDAQ:RETAReata Pharmaceuticals Inc
14/06/202300h27Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:RETAReata Pharmaceuticals Inc
13/06/202312h45Business WireReata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development OfficerNASDAQ:RETAReata Pharmaceuticals Inc
09/06/202311h45PR Newswire (US)RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsNASDAQ:RETAReata Pharmaceuticals Inc
07/06/202322h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RETAReata Pharmaceuticals Inc
07/06/202311h45PR Newswire (US)INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Reata Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: RETA)NASDAQ:RETAReata Pharmaceuticals Inc
06/06/202322h31Business WireReata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:RETAReata Pharmaceuticals Inc
15/05/202322h36Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:RETAReata Pharmaceuticals Inc
10/05/202312h40Business WireReata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development ProgramsNASDAQ:RETAReata Pharmaceuticals Inc
02/05/202323h45Business WireReata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023NASDAQ:RETAReata Pharmaceuticals Inc
28/04/202312h23Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RETAReata Pharmaceuticals Inc
28/04/202312h23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RETAReata Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RETA

Dernières Valeurs Consultées

EU
RNO
Renault
EU
HO
Thales
SPI
SP500
S&P 500
EU
CAP
Capgemini
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
EU
AF
Air FranceKLM
EU
BNP
BNP Paribas
NYSE
DIS
Walt Disney
EU
VK
Vallourec
COIN
ETHUSD
Ethereum
NASDAQ
MSFT
Microsoft
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés